Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Oncology (VSTM) has appointed Matthew E. Ros as chief operating officer as the company prepares for its transition to a commercial-stage organization. Ros, who brings over 35 years of biopharmaceutical industry experience, will report to CEO Dan Paterson and join the executive leadership team.
The appointment comes as Verastem prepares for a potential mid-2025 product launch of a first-in-class treatment combination for low-grade serous ovarian cancer. Ros's previous experience includes serving as CEO at FORE Biotherapeutics and executive roles at Epizyme, Sanofi-Genzyme, and ARIAD Pharmaceuticals, where he led commercial organizations and secured FDA approvals.
The company focuses on advancing medicines for RAS/MAPK pathway-driven cancers, with their upcoming treatment targeting a rare cancer that currently has no approved specific treatments.
Verastem Oncology (VSTM) ha nominato Matthew E. Ros come chief operating officer mentre l'azienda si prepara per la sua transizione verso un'organizzazione commerciale. Ros, che vanta oltre 35 anni di esperienza nel settore biopharmaceutico, riporterà al CEO Dan Paterson e si unirà al team di leadership esecutiva.
La nomina arriva mentre Verastem si prepara per un potenziale lancio di prodotto a metà 2025 di una combinazione di trattamenti innovativi per il cancro ovarico sieroso di basso grado. L'esperienza precedente di Ros include il ruolo di CEO presso FORE Biotherapeutics e posizioni esecutive presso Epizyme, Sanofi-Genzyme e ARIAD Pharmaceuticals, dove ha guidato organizzazioni commerciali e ottenuto approvazioni dalla FDA.
L'azienda si concentra nel promuovere farmaci per i cancro a pathway RAS/MAPK, con il loro prossimo trattamento mirato a un cancro raro che attualmente non ha trattamenti specifici approvati.
Verastem Oncology (VSTM) ha nombrado a Matthew E. Ros como director de operaciones mientras la empresa se prepara para su transición a una organización en etapa comercial. Ros, que aporta más de 35 años de experiencia en la industria biofarmacéutica, reportará al CEO Dan Paterson y se unirá al equipo de liderazgo ejecutivo.
El nombramiento llega mientras Verastem se prepara para un posible lanzamiento de producto a mediados de 2025 de una combinación de tratamientos de primera clase para el cáncer de ovario seroso de bajo grado. La experiencia previa de Ros incluye haber sido CEO de FORE Biotherapeutics y roles ejecutivos en Epizyme, Sanofi-Genzyme y ARIAD Pharmaceuticals, donde lideró organizaciones comerciales y aseguró aprobaciones de la FDA.
La compañía se centra en avanzar en medicamentos para cánceres impulsados por la vía RAS/MAPK, con su próximo tratamiento dirigido a un cáncer raro que actualmente no tiene tratamientos específicos aprobados.
Verastem Oncology (VSTM)는 회사가 상장 기업으로의 전환을 준비하면서 Matthew E. Ros를 최고 운영 책임자로 임명했습니다. Ros는 35년 이상의 생물의약 산업 경험을 가지고 있으며, CEO Dan Paterson에게 보고하고 임원 리더십 팀에 합류할 것입니다.
이번 임명은 Verastem이 2025년 중반에 저급 점막 난소암을 위한 첫 번째 혁신적 치료 조합을 출시할 가능성에 대비하고 있는 가운데 이루어졌습니다. Ros는 FORE Biotherapeutics의 CEO로 재직했으며 Epizyme, Sanofi-Genzyme, ARIAD Pharmaceuticals와 같은 곳에서 상업 부문에서 활동하며 FDA 승인을 받는 역할을 맡았습니다.
이 회사는 RAS/MAPK 경로가 주도하는 암을 위한 의약품 개발에 집중하고 있으며, 곧 출시될 치료제는 현재 승인된 특정 치료제가 없는 희귀 암을 대상으로 하고 있습니다.
Verastem Oncology (VSTM) a nommé Matthew E. Ros au poste de directeur des opérations alors que l'entreprise se prépare à sa transition vers une organisation commerciale. Ros, qui possède plus de 35 ans d'expérience dans l'industrie biopharmaceutique, relèvera du CEO Dan Paterson et rejoindra l'équipe de direction exécutive.
Cette nomination survient alors que Verastem se prépare à un lancement de produit prévu pour mi-2025 d'une combinaison de traitement de première classe pour le cancer ovarien séreux de bas grade. L'expérience antérieure de Ros comprend son rôle en tant que CEO chez FORE Biotherapeutics et des postes exécutifs chez Epizyme, Sanofi-Genzyme et ARIAD Pharmaceuticals, où il a dirigé des organisations commerciales et obtenu des approbations de la FDA.
L'entreprise se concentre sur l'avancement de médicaments pour les cancers dirigés par la voie RAS/MAPK, avec leur prochain traitement visant un cancer rare qui n'a actuellement aucun traitement spécifique approuvé.
Verastem Oncology (VSTM) hat Matthew E. Ros zum Chief Operating Officer ernannt, während das Unternehmen sich auf den Übergang zu einer kommerziellen Organisation vorbereitet. Ros bringt über 35 Jahre Erfahrung in der biopharmazeutischen Industrie mit und wird an CEO Dan Paterson berichten und dem Führungsteam beitreten.
Die Ernennung erfolgt, während Verastem sich auf eine mögliche Produkteinführung Mitte 2025 einer bahnbrechenden Behandlungscombination für niedriggradigen serösen Eierstockkrebs vorbereitet. Ros' frühere Erfahrung umfasst die Tätigkeit als CEO bei FORE Biotherapeutics sowie Führungspositionen bei Epizyme, Sanofi-Genzyme und ARIAD Pharmaceuticals, wo er kommerzielle Organisationen leitete und FDA-Zulassungen sicherte.
Das Unternehmen konzentriert sich darauf, Medikamente für von der RAS/MAPK-Weg abhängigen Krebserkrankungen weiterzuentwickeln, wobei ihre bevorstehende Behandlung auf eine seltene Krebserkrankung abzielt, für die derzeit keine spezifischen, genehmigten Behandlungen existieren.
- Strategic appointment of experienced COO with 35+ years in biopharmaceutical commercialization
- Planned launch of first-in-class treatment for low-grade serous ovarian cancer by mid-2025
- Targeting an unmet medical need with no currently approved specific treatments
- No immediate revenue generation until potential mid-2025 product launch
- Success dependent on pending regulatory approvals
Insights
The appointment of Matthew Ros as COO, while a significant executive hire, represents a strategic positioning move rather than an immediate market catalyst. His extensive 35-year track record in commercialization and operational experience, particularly in transitioning companies from development to commercial stages, aligns with Verastem's anticipated mid-2025 product launch timeline.
The key value proposition lies in the company's preparation for commercializing a first-in-class treatment combination for low-grade serous ovarian cancer. This rare cancer indication currently lacks approved specific treatments, potentially creating a protected market opportunity. Ros's experience with FDA approvals and successful oncology product launches at Bristol-Myers Squibb, ARIAD Pharmaceuticals and Sanofi-Genzyme strengthens Verastem's commercial readiness.
With a relatively modest market cap of
New executive leadership supports the company’s transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025.
“We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance our clinical programs,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “Matt is an accomplished biopharmaceutical executive with extensive experience driving business transformation. His expertise will drive invaluable operational excellence as we prepare to launch a potential first-in-class treatment combination for patients with low-grade serous ovarian cancer, a rare cancer with no approved treatments specifically for this disease, and simultaneously progress programs and partnerships to address cancers driven by the RAS/MAPK-pathway that often lack treatment options.”
Mr. Ros brings more than 35 years of commercialization and operational experience in the biopharmaceutical industry with a track record of capital-driving success at publicly traded biopharmaceutical companies undergoing evolutions from early stage to registrational development. Most recently, Mr. Ros served as chief executive officer and board director at FORE Biotherapeutics, an early, clinical-stage oncology company focused on recurrent central nervous system malignancies. Previously, Mr. Ros held executive leadership roles at prominent biopharmaceutical companies, including Epizyme, Sanofi-Genzyme, and ARIAD Pharmaceuticals, where he built fully integrated commercial organizations, delivered strategic collaborations, secured multiple FDA approvals, and supported successful launches. Mr. Ros began his career at Bristol-Myers Squibb where he held positions of increasing responsibility within its Oncology division, contributing to and championing the successful launches of many leading oncology brands. In addition to his executive experience, Mr. Ros serves as a board member at Cogent Biosciences, contributing to its Audit, Nomination, and Governance Committees, and previously served on the Board of Trustees of CancerCARE.
“My life’s work has been focused on fostering the growth and operational strength of companies dedicated to changing cancer and improving the lives of people living with cancer,” said Mr. Ros. “I am excited to be joining Verastem Oncology to help build on the company’s momentum and create tremendous opportunities for the future while having the potential to bring a meaningful new treatment option to women living with a rare ovarian cancer.”
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115045259/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
When is Verastem Oncology (VSTM) planning to launch its new ovarian cancer treatment?
What type of cancer treatment is VSTM developing?
Who is the new Chief Operating Officer at Verastem Oncology (VSTM)?
What is unique about VSTM's ovarian cancer treatment?
